Article Text

Download PDFPDF
m6A RNA methylation controls salivary gland epithelial cell function and has a protective role in Sjögren’s disease

Abstract

Objectives The RNA epitranscriptomic modification known as N6-methyladenosine (m6A) represents a novel mechanism of gene regulation that is poorly understood in human autoimmune diseases. Our research explores the role of this RNA m6A modification in salivary gland epithelial cells (SGEC) and its impact on the pathogenesis of Sjögren’s disease (SjD).

Methods SGECs from SjD patients and controls were analysed for m6A writers METTL3 and METTL14 expression using RNA-seq, quantitative PCR and immunohistochemistry. Functional assays assessed the impact of METTL3 knockdown or pharmacological inhibition on proinflammatory gene expression and immune cell interactions (using transwell and coculture systems). Mechanistic studies examined METTL3-mediated m6A modifications in double-stranded RNA (dsRNA) formation through immunofluorescence. Unsupervised clustering identified patterns of interferon activation in salivary glands and their correlation with m6A writers.

Results METTL3 and METTL14 were elevated in SGEC from SjD patients in comparison to controls. Paradoxically, inhibiting METTL3 increased proinflammatory gene expression, enhancing SGEC’s ability to attract immune cells and activate B cells. Conversely, inhibiting the eraser FTO had the opposite effect. METTL3-mediated m6A modifications prevented dsRNA formation and IFN signalling activation. SGEC from SjD showed insufficient METTL3 upregulation compared with controls in response to inflammatory triggers, indicating a limited capacity to regulate the inflammatory response. SjD patients with elevated disease activity and higher interferon signature exhibit reduced METTL3 expression.

Conclusions Impairment of m6A modifications in SGEC in response to inflammatory triggers favour the formation of dsRNA, potentially amplifying the interferon loop and contributing to SjD pathogenesis.

  • Autoimmune Diseases
  • Cytokines
  • Inflammation
  • Sjogren's Syndrome
  • Autoimmunity

Data availability statement

Data are available in a public, open access repository. Data are available on reasonable request. NS-SV-TT-AC and NS-SV-TT-DC cells are available by MTA from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Dental and Craniofacial Research (NIDCR). STM2457, STM2120 and STM3006 are under MTA from STORM THERAPEUTICS LTD. All other reagents are commercially available. RNAseq data generated in this study are available on reasonable request, rami.bechara@universite-paris-saclay.fr. RNAseq data from these studies GSE23117 (48), GSE154926 (49), GSE157159 (50), GSE173808 (51) are publicly available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.